Dr Reddy's Laboratories SG&A Expenses 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Dr Reddy's Laboratories sg&a expenses for the quarter ending September 30, 2024 were $0.274B, a 21.02% increase year-over-year.
- Dr Reddy's Laboratories sg&a expenses for the twelve months ending September 30, 2024 were $1.030B, a 18.72% increase year-over-year.
- Dr Reddy's Laboratories annual sg&a expenses for 2024 were $0.926B, a 11.84% increase from 2023.
- Dr Reddy's Laboratories annual sg&a expenses for 2023 were $0.828B, a 1.22% increase from 2022.
- Dr Reddy's Laboratories annual sg&a expenses for 2022 were $0.818B, a 9.5% increase from 2021.
Dr Reddy's Laboratories Annual SG&A Expenses
(Millions of US $) |
| 2024 |
$926 |
| 2023 |
$828 |
| 2022 |
$818 |
| 2021 |
$747 |
| 2020 |
$665 |
| 2019 |
$707 |
| 2018 |
$720 |
| 2017 |
$715 |
| 2016 |
$690 |
| 2015 |
$683 |
| 2014 |
$622 |
| 2013 |
$616 |
| 2012 |
$567 |
| 2011 |
$532 |
| 2010 |
$501 |
| 2009 |
$ |
Dr Reddy's Laboratories Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$274 |
| 2024-06-30 |
$272 |
| 2024-03-31 |
$241 |
| 2023-12-31 |
$243 |
| 2023-09-30 |
$226 |
| 2023-06-30 |
$216 |
| 2023-03-31 |
$206 |
| 2022-12-31 |
$219 |
| 2022-09-30 |
$207 |
| 2022-06-30 |
$196 |
| 2022-03-31 |
$193 |
| 2021-12-31 |
$207 |
| 2021-09-30 |
$215 |
| 2021-06-30 |
$202 |
| 2021-03-31 |
$204 |
| 2020-12-31 |
$197 |
| 2020-09-30 |
$177 |
| 2020-06-30 |
$169 |
| 2020-03-31 |
$73 |
| 2019-12-31 |
$179 |
| 2019-09-30 |
$238 |
| 2019-06-30 |
$175 |
| 2019-03-31 |
$186 |
| 2018-12-31 |
$167 |
| 2018-09-30 |
$177 |
| 2018-06-30 |
$177 |
| 2018-03-31 |
$179 |
| 2017-12-31 |
$187 |
| 2017-09-30 |
$172 |
| 2017-06-30 |
$182 |
| 2017-03-31 |
$189 |
| 2016-12-31 |
$167 |
| 2016-09-30 |
$177 |
| 2016-06-30 |
$182 |
| 2016-03-31 |
$164 |
| 2015-12-31 |
$183 |
| 2015-09-30 |
$170 |
| 2015-06-30 |
$173 |
| 2015-03-31 |
$142 |
| 2014-12-31 |
$172 |
| 2014-09-30 |
$176 |
| 2014-06-30 |
$178 |
| 2014-03-31 |
$159 |
| 2013-12-31 |
$169 |
| 2013-09-30 |
$146 |
| 2013-06-30 |
$148 |
| 2013-03-31 |
$169 |
| 2012-12-31 |
$159 |
| 2012-09-30 |
$143 |
| 2012-06-30 |
$145 |
| 2012-03-31 |
$119 |
| 2011-12-31 |
$141 |
| 2011-09-30 |
$158 |
| 2011-06-30 |
$149 |
| 2011-03-31 |
$154 |
| 2010-12-31 |
$142 |
| 2010-09-30 |
$118 |
| 2010-06-30 |
$118 |
| 2010-03-31 |
$153 |
| 2009-12-31 |
$117 |
| 2009-09-30 |
$108 |
| 2009-06-30 |
$123 |
| 2009-03-31 |
$65 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.978B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
